临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 74431-23-5

Imipenem

中文名称:亚胺培南(一水物)
CAS号:74431-23-5
分子式: C12H17N3O4S.H2O 分子量: 317.36
产品形式: hydrate
研发状态: Recruiting
研发用途: Cystic Fibrosis; Pneumonia Bacterial
研究机构: Hartford Hospital; Merck Sharp & Dohme LLC; Q2 Solutions; Connecticut Children''s Medical Center; St. Christopher''s Hospital for Children; University of Texas Southwestern Medical Center; University of Pittsburgh Medical Center; Indiana University Health Methodist Hospital; James Whitcomb Riley Hospital for Children
研发日期: January 3 2023
研发阶段: Phase 4
Imipenem acts as an inhibitor of AmpC β-lactamase and is an antibiotic useful for the treatment of a number of bacterial infections.

CAS: 743461-65-6

Batefenterol

CAS号:743461-65-6
分子式: C40H42ClN5O7 分子量: 740.24
产品形式: Free Base
研发状态: Completed
研发用途: Pulmonary Disease Chronic Obstructive
研究机构: GlaxoSmithKline
研发日期: February 19 2014
研发阶段: Phase 1
Batefenterol (GSK961081, TD-5959) is both a muscarinic receptor antagonist and a β2-adrenoceptor agonist with Ki of 1.4 nM, 1.3 nM and 3.7 nM for hM2, hM3 muscarinic receptors and hβ2-adrenoceptor, respectively.

CAS: 74252-25-8

Indometacin Sodium

中文名称:吲哚美辛
CAS号:74252-25-8
分子式: C19H21ClNNaO7 分子量: 433.82
产品形式: sodium salt trihydrate
研发状态: Completed
研发用途: Pancreatitis; Cholangiopancreatography Endoscopic Retrograde; Indomethacin
研究机构: The First Affiliated Hospital of Soochow University
研发日期: November 1 2022
研发阶段: Not Applicable
Indometacin Sodium (Indomethacin Sodium) is the sodium salt of indomethacin, which is a non-selective, reversible, and competitive inhibitor of cyclooxygenases 1 and 2 with anti-inflammatory, analgesic-antipyretic and tocolytic effects.

CAS: 74191-85-8

Doxazosin

中文名称:多沙唑嗪
CAS号:74191-85-8
分子式: C23H25N5O5 分子量: 451.48
产品形式: Free Base
研发状态: Completed
研发用途: Allergic Rhinitis
研究机构: University of Dundee
研发日期: Sep-13
研发阶段: Phase 4
Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

CAS: 741713-40-6

R547

中文名称:[4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮
CAS号:741713-40-6
分子式: C18H21F2N5O4S 分子量: 441.45
产品形式: free base
研发状态: Completed
研发用途: Neoplasms
研究机构: Hoffmann-La Roche
研发日期: May-05
研发阶段: Phase 1
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.

CAS: 74103-06-3

Ketorolac

中文名称:酮咯酸
CAS号:74103-06-3
分子式: C15H13N1O3 分子量: 255.27
产品形式: free base
研发状态: Recruiting
研发用途: Renal Colic; Flank Pain; Emergencies; Analgesia
研究机构: Hackensack Meridian Health
研发日期: December 21 2023
研发阶段: Phase 4
Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.